HIV infectious disease

This early-stage trial tested an experimental HIV vaccine in 44 healthy adults to see if it was safe and triggered an immune response. The vaccine uses a piece of the HIV virus (fusion peptide) to train the body's defenses. The study was terminated early, so the full results are …

This study aimed to find the best way to help transgender women living with HIV reach undetectable viral levels. Participants received either text messages, help from a peer health navigator, or both. The trial was ended early, so results are limited.

This clinical trial investigates whether a 3-month combination of clofazimine and rifapentine can effectively treat drug-susceptible tuberculosis (TB) compared to the standard 6-month regimen. The study includes adults with pulmonary TB, some of whom also have HIV. Researchers ar…

This study tests whether adding peer-based counseling to standard HIV and opioid treatment helps people who inject drugs stay on their medications and achieve viral suppression. Participants receive either enhanced usual care or extra support from a peer counselor. The goal is to…

This study aimed to see if liver transplantation is possible and safe for people infected with both HIV and hepatitis C. Fifteen patients were enrolled to track survival, virus behavior, and drug interactions after transplant. The goal was to understand how these two viruses inte…

This study compared two HIV treatment approaches in people who had never taken HIV drugs before. One group started with a three-drug combo for 16 weeks, then switched to a two-drug combo. The other group took a two-drug combo from the start. The goal was to see if the first appro…

This study looked at whether switching from a standard HIV drug combination to a different one (Delstrigo) could improve cholesterol, body fat, and blood sugar in people with HIV. The study planned to enroll 60 adults whose HIV was already well-controlled. Participants were rando…

This study tested whether a once-weekly oral combination of two experimental drugs (lepetegravir and lenacapavir pacfosacil) could control HIV as well as the standard daily pill Biktarvy. It enrolled 73 people newly diagnosed with HIV-1 who had never taken HIV medication. The stu…

This study looked at how feminizing hormone therapy (estradiol) interacts with HIV medications in transgender women living with HIV. It included 93 participants who were already on HIV treatment and gave them standardized estradiol doses for up to 48 weeks. The goal was to see if…

This study looked at whether different medications for opioid use disorder (methadone, buprenorphine/naloxone, or naltrexone) could reduce immune system inflammation in people with HIV. Researchers measured changes in blood markers of immune activation over 24 weeks. The trial wa…

This study tested whether switching to a two-drug HIV treatment (raltegravir plus maraviroc) could reduce belly fat (lipohypertrophy) in people whose HIV was already well-controlled. It included 48 adults on stable HIV therapy for at least 5 years. The study was stopped early, so…

This early-phase trial tested two immunotherapy drugs, ipilimumab and nivolumab, in people with HIV who had advanced solid tumors or Hodgkin lymphoma that had spread or come back. The goal was to find the safest dose and see if the combination could shrink tumors. The study was t…

This early-stage trial tests two experimental vaccines, HB-502 and HB-501, designed to teach the immune system to recognize and attack HIV. The study includes 30 people with HIV who are already on suppressive antiretroviral therapy. Participants receive injections every 8 weeks f…

This study looked at whether weekly injections of PRO 140, taken with standard HIV medications, could keep the virus under control over the long term. It enrolled 43 people who had already completed an earlier PRO 140 study and had undetectable virus levels. The study was termina…

This study tested whether HIV patients who already had the virus under control could switch to weekly injections of leronlimab (PRO 140) instead of their usual daily pills. The goal was to see if the drug alone could keep the virus suppressed safely over a longer period. The tria…

This study tested two experimental drugs, budigalimab and ABBV-382, in people with HIV who were stable on standard therapy. Participants stopped their usual HIV medications to see if the new drugs could keep the virus under control. The trial was terminated early, so it's unclear…

This was a small, early-phase study testing an experimental HIV drug called GS-1219 in just 4 people living with HIV-1. The goal was to check the drug's safety and how well it fights the virus. The study was terminated early, so results are very limited.

This study tested a program to help Virginia Medicaid enrollees with HIV fill their antiretroviral prescriptions on time. The program offered support from providers, pharmacies, and community groups, with extra help for those who were very late refilling. Only 4 people enrolled b…

This study tested an experimental HIV drug called VH3739937 in 21 adults with HIV who had never taken HIV medication before. The goal was to see how well the drug lowered the virus level in the blood over a short time. The trial was stopped early, and results are limited.

This study tested whether a single antibody called PRO 140 could keep HIV under control in 20 adults who had been stable on standard combination therapy. Participants stopped their usual HIV pills and received only PRO 140 infusions. The trial was stopped early, and the main goal…

This study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The trial aimed to see if the drug could reduce liver fat over 24 weeks. However, the study was terminated early and only enrolled 4 participants, so no meaning…

This study is testing a new medical device called MagIA IBC that uses a single drop of blood from a finger prick to screen for HIV, hepatitis B, and hepatitis C at the same time. Researchers will enroll 252 adults who are known or suspected to have one of these infections. The go…

This phase 3 study tested a daily pill called F/TAF (Descovy) to prevent HIV infection in nearly 5,400 men and transgender women who have sex with men and are at high risk. Participants took either F/TAF or the existing prevention drug Truvada. The goal was to see if F/TAF is as …

This study tested a program called Malkia Klabu ("Queen Club") in Tanzania. The program made local drug shops more welcoming for adolescent girls and young women, so they could easily get HIV prevention services and contraception. Researchers looked at whether this approach incre…

This study tested a once-monthly pill called islatravir to prevent HIV infection in cisgender men and transgender women who have sex with men and are at high risk. About 494 participants were enrolled, but the trial was terminated early. The main goal was to check safety and see …

This study tested a mobile-friendly tool that helps young Black men and transwomen who have sex with men or transwomen pick the best HIV testing method for them, such as self-testing or clinic testing. The goal was to see if this personalized recommendation could increase how oft…

This study tested a program to help HIV-negative transgender women and men who have sex with men who also have a substance use disorder stick with PrEP, a daily pill or shot that prevents HIV. Participants received counseling and text support, with extra help for those who strugg…

This study tested a new monthly pill (islatravir) to see if it could prevent HIV infection better than a daily pill in 730 women at high risk. The trial was stopped early, so results are limited. The goal was to offer a more convenient prevention option.

This study tested whether synthetic cannabidiol (CBD) could help people living with HIV who have a condition called alexithymia, which makes it hard to recognize and describe emotions. Participants took either CBD or a placebo for 4 weeks. The goal was to see if CBD could improve…

This study tested whether a group therapy program, led by trained youth leaders, could improve mental health and help young people with HIV stick to their medication. About 484 youth in low-resource settings took part. The program used trauma-informed counseling adapted to local …

This study aimed to see if acceptance and commitment therapy (ACT), a type of talk therapy, could help HIV-positive men with mental health issues like stress and anxiety. Only one person enrolled before the study was stopped early. Because of this, no meaningful results were obta…

This study looked at how HIV and tuberculosis (TB) medications are processed in the bodies of pregnant women and new mothers. Researchers measured drug levels in the blood of 205 women during pregnancy and after delivery to see if standard doses are effective. The goal was to gat…

This study compared signs of aging in 123 HIV-infected adults to the general population. Researchers measured bone density, muscle strength, skin changes, and thinking abilities. The goal was to understand if HIV speeds up aging in these areas. No new treatment was tested; it was…

This study looked at how the mpox virus spreads and how the immune system responds in people with advanced HIV. Researchers tracked the virus in different body samples and measured immune markers to better understand severe illness. The goal is to use these findings to improve tr…

This study tested a web-based program to help Black women in Texas use HIV and STI home tests and connect to treatment or PrEP. The program included five sessions with goal-setting and action plans. Only 31 women enrolled before the study was stopped early, so the findings are li…

This pilot study tested several low-cost behavioral nudges, like videos and text messages, to encourage HIV retesting among 98 adults at higher risk of HIV in rural Kenya and Uganda. The goal was to see which approaches were acceptable and feasible, so the best ones could be used…

This study looked at how much physical activity and sitting time people with HIV in New York City get. Participants wore a small device called an accelerometer for a week to track their movement. The goal was to understand how activity levels relate to overall health. The study w…

This study looked at bone density in HIV-positive men to see if antiretroviral drugs cause bone thinning. Researchers compared men starting HIV treatment with those not yet on therapy over two years. The goal was to understand why bone loss is more common in HIV patients.